Salvage Therapy Trials in Invasive Fungal Disease: Challenges and Opportunities
Open Access
- 1 December 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (11) , 1456-1460
- https://doi.org/10.1086/508468
Abstract
The purpose of a clinical trial is to distinguish the effect of a medical intervention on clinical outcomes from the effect of other factors, such as the natural history of the disease or biased observations. The degree to which the causal relationship between the intervention and the outcome is free of extraneous influences is termed internal validity [1]. For a clinical trial to have internal validity, it should adhere to several well-accepted scientific principles. These include (1) a clear statement of the objective of the trial, (2) a meaningful, quantitative comparison with a control, (3) confirmation that the patient has the disease under study, (4) baseline comparability of patients at the start of the trial, (5) minimization of bias and confounding, (6) measurement of well-defined and reliable end points that reflect clinically meaningful outcomes important to patients, and (7) appropriate statistical analysis of trial results [2]. For a trial to provide results that one can extrapolate to clinical practice (i.e., for the trial to have external validity), it must adhere to these principles of internal validity.Keywords
This publication has 10 references indexed in Scilit:
- Issues Related to the Design and Interpretation of Clinical Trials of Salvage Therapy for Invasive Mold InfectionClinical Infectious Diseases, 2006
- Itraconazole versus Fluconazole for Antifungal ProphylaxisAnnals of Internal Medicine, 2004
- A perfect correlate does not a surrogate makeBMC Medical Research Methodology, 2003
- The pros and cons of noninferiority trialsFundamental & Clinical Pharmacology, 2003
- Forum Report: Issues in the Design of Trials of Drugs for the Treatment of Invasive AspergillosisClinical Infectious Diseases, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Unequal group sizes in randomised trials: guarding against guessingThe Lancet, 2002
- A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940sBMJ, 1999
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Bias in Treatment Assignment in Controlled Clinical TrialsNew England Journal of Medicine, 1983